Cullen/Frost Bankers’s Halozyme HALO Stock Holding History

Cullen/Frost Bankers’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$17.3K	Buy	221 +5	+2%	+$341	﹤0.01%	1081
2026 Q1	$14K	Buy	216 +28	+15%	+$1.97K	﹤0.01%	1056
2025 Q4	$12.7K	Buy	188 +8	+4%	+$538	﹤0.01%	1088
2025 Q3	$13.2K	Buy	+180	New	+$12K	﹤0.01%	1029
2023 Q3	–	Sell	-1,000	Closed	-$36.1K	–	1173
2023 Q2	$36.1K	Hold	1,000	–	–	﹤0.01%	778
2023 Q1	$38.2K	Hold	1,000	–	–	﹤0.01%	765
2022 Q4	$56.9K	Hold	1,000	–	–	﹤0.01%	676
2022 Q3	$40K	Buy	+1,000	New	+$44.2K	﹤0.01%	744

Other funds holding HALO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

MMC

Mizuho Markets Cayman Grand Cayman, Cayman Islands $2.67B AUM 103.47% 1-Year Est. Return

Cullen/Frost Bankers's HALO Position: Q2 2026 in Review

Cullen/Frost Bankers increased its Halozyme (HALO) stake by 2.3% in Q2 2026, buying an estimated $341 and bringing the position to 221 shares worth $17.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1081.

Cullen/Frost Bankers first reported a position in HALO in Q3 2022 and has held it in 8 quarters since. The position peaked at $56.9K in Q4 2022. 368 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

Cullen/Frost Bankers held 221 shares of Halozyme worth $17.3K as of Q2 2026.
Cullen/Frost Bankers bought 5 Halozyme shares in Q2 2026, an estimated $341.
Halozyme made up ﹤0.01% of Cullen/Frost Bankers's portfolio in Q2 2026, its #1081 holding.
Cullen/Frost Bankers first reported a position in Halozyme in Q3 2022 and has held it in 8 quarters since.
Cullen/Frost Bankers's Halozyme position peaked at $56.9K in Q4 2022.
368 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Cullen/Frost Bankers's 13F filing for Q2 2026, filed 27 Jul 2026.